Evidence map›Paper›PMID 41381412›Full record

ArticleCell death & disease2025

Mice carrying nonsense mutant p53 develop frequent multicentric or metastatic tumors.

Charlotte Strandgren, Veronica Rondahl, Ann-Sophie Oppelt, Susanne Öhlin, Angelos Heldin, Klas G Wiman

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. RiboScreenBiomedicines · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Charlotte StrandgrenDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0009-0002-3127-1578
Veronica RondahlDepartment of Animal Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-0129-275X
Ann-Sophie OppeltDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Susanne ÖhlinDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Angelos HeldinDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Klas G WimanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Klas.Wiman@ki.se.ORCID http://orcid.org/0000-0002-7113-524X

Funding

Barncancerfonden (Swedish Childhood Cancer Foundation) PR2020-0042Cancerfonden (Swedish Cancer Society) 21 1473 Pj 01 HEC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 694825Vetenskapsrådet (Swedish Research Council) 2021-02064
6 · The paper itself

Abstract

The TP53 tumor suppressor gene is mutated in a large fraction of human tumors. Close to 11% of TP53 mutations are nonsense mutations, causing premature termination of protein synthesis and expression of truncated inactive p53 protein. The most common TP53 nonsense mutation in human cancer is R213X. To study the impact of TP53 nonsense mutations in vivo, we generated mice harboring the Trp53 nonsense mutation R210X that corresponds to human TP53-R213X. Initially, Trp53

Indexed as

Codon, NonsenseNeoplasmsTumor Suppressor Protein p53AnimalsFemaleHomozygoteHumansLoss of HeterozygosityMaleMiceNeoplasm MetastasisCodon, NonsenseTrp53 protein, mouseTumor Suppressor Protein p53

Identifiers

PMID41381412
PMCPMC12830816

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.